Selective Interarterial Radiation Therapy (SIRT) in Colorectal Liver Metastases: How Do We Monitor Response?
Table 1
Response evaluation criteria in solid tumours (RECIST) [19], world health organisation (WHO) [19], and european association for study of the Liver (EASL) [20].
RECIST change in sum of the longest diameters
WHO change in sum of products
EASL
Complete response (CR)
Disappearance of all target lesions at 4 weeks
Disappearance of all target lesions at 4 weeks
100% necrosis of target lesions and no new lesions
Partial response (PR)
30% decrease in the Longest Diameter (LD) of target lesions at 4 weeks
50% decrease confirmed at 4 weeks
50–99% increase in necrosis
Stable disease (SD)
Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD
Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD
<50% increase in necrosis
Progressive disease (PD)
At least a 20% increase in the LD of target lesions; no CR, PR, or SD documented before increase
25% increase; no CR, PR, or SD documented before increase
